Recombinant antibody fragment therapeutics: Current status and future prospects of scFv, nanobody, and mimotopes

Ghaderi, Hajarossadat; Alipour, Atefeh; Mohammadi Zadeh Holagh, Arya; Kazemi lomedasht, Fatemeh; Abdollahpour-Alitappeh, Meghdad; Kaghazian, Hooman; Shahsavarani, Hosein

doi:10.1016/j.jddst.2023.105009

Cited by 3 publications

(1 citation statement)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14,15 With the development of antibody technology, some emerging affinity reagents derived from natural antibodies, such as single-chain fragment variable (ScFv) antibody, nanobody, and artificial protein scaffold, show improved performances in terms of stability, target range, immunogenicity, and tissue penetration compared with natural antibodies. 16–23 Antibody-derived affinity reagents retain their original affinity for the targets by intercepting the bioactive units in antibodies, and usually show effectively improved stability, enhanced tissue permeability and reduced immunogenicity. 24 In addition, innovations of antibody production technologies, such as phage/microbial display technology and genetic engineering, have greatly reduced the manufacture time; typically in hybridoma technology, the period can be reduced from a few months to one week once screened.…”

Section: Introductionmentioning

confidence: 99%

Aptamer-based assembly systems for SARS-CoV-2 detection and therapeutics

Dong,

Wang,

Chen

et al. 2024

Chem. Soc. Rev.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Aptamer-based assembly systems for SARS-CoV-2 detection and therapeutics

Dong,

Wang,

Chen

et al. 2024

Chem. Soc. Rev.

View full text Add to dashboard Cite

show abstract

What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible Interactions. The Review

Szupryczyński,

Czeleń,

Jeliński

et al. 2024

IJN

View full text Add to dashboard Cite

Over the course of several decades, anticancer treatment with chemotherapy drugs for lung cancer has not changed significantly. Unfortunately, this treatment prolongs the patient’s life only by a few months, causing many side effects in the human body. It has also been proven that drugs such as Cisplatin, Carboplatin, Oxaliplatin and others can react with other substances containing an aromatic ring in which the nitrogen atom has a free electron group in its structure. Thus, such structures may have a competitive effect on the nucleobases of DNA. Therefore, scientists are looking not only for new drugs, but also for new alternative ways of delivering the drug to the cancer site. Nanotechnology seems to be a great hope in this matter. Creating a new nanomedicine would reduce the dose of the drug to an absolute minimum, and thus limit the toxic effect of the drug; it would allow for the exclusion of interactions with competitive compounds with a structure similar to nucleobases; it would also permit using the so-called targeted treatment and bypassing healthy cells; it would allow for the introduction of other treatment options, such as radiotherapy directly to the cancer site; and it would provide diagnostic possibilities. This article is a review that aims to systematize the knowledge regarding the anticancer treatment of lung cancer, but not only. It shows the clear possibility of interactions of chemotherapeutics with compounds competitive to the nitrogenous bases of DNA. It also shows the possibilities of using nanostructures as potential Platinum drug carriers, and proves that nanomedicine can easily become a new medicinal product in personalized medicine.

show abstract

Single chain fragment variable, a new theranostic approach for cardiovascular diseases

Zahid,

Wang,

Cai

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) remain a significant global health challenge, leading to substantial morbidity and mortality. Despite recent advancements in CVD management, pharmaceutical treatments often suffer from poor pharmacokinetics and high toxicity. With the rapid progress of modern molecular biology and immunology, however, single-chain fragment variable (scFv) molecule engineering has emerged as a promising theranostic tool to offer specificity and versatility in targeting CVD-related antigens. To represent the latest development on the potential of scFv in the context of CVDs, this review summarized the new mechanism of action and applications as therapeutic, as well as diagnostic agents. Furthermore, the advantages of scFv, including its small size, ease of modification, and ability to be engineered for enhanced affinity and specificity, are also described. Finally, such challenges as immunogenicity, stability, and scalability, alongside strategies to overcome these hurdles, are deeply scrutinized to provide safer and more effective strategies for the diagnosis and treatment of the incurable CVDs.

show abstract

Recombinant antibody fragment therapeutics: Current status and future prospects of scFv, nanobody, and mimotopes

Cited by 3 publications

References 90 publications

Aptamer-based assembly systems for SARS-CoV-2 detection and therapeutics

Aptamer-based assembly systems for SARS-CoV-2 detection and therapeutics

What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible Interactions. The Review

Single chain fragment variable, a new theranostic approach for cardiovascular diseases

Contact Info

Product

Resources

About